Avinger Inc. (NASDAQ:AVGR) shares saw strong trading volume on Wednesday . 1,869,401 shares traded hands during trading, an increase of 619% from the previous session’s volume of 260,162 shares.The stock last traded at $6.86 and had previously closed at $11.43.

Several research firms have recently commented on AVGR. Zacks Investment Research raised shares of Avinger from a “sell” rating to a “hold” rating in a report on Thursday, May 19th. Canaccord Genuity reaffirmed a “buy” rating and issued a $20.00 price target on shares of Avinger in a report on Wednesday, March 30th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $18.75.

The stock’s 50-day moving average price is $11.25 and its 200-day moving average price is $13.05. The stock’s market capitalization is $87.45 million.

Avinger (NASDAQ:AVGR) last issued its quarterly earnings data on Wednesday, May 4th. The medical device company reported ($1.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.17) by $0.11. On average, equities research analysts predict that Avinger Inc. will post ($4.22) earnings per share for the current fiscal year.

In other news, Director Donald A. Lucas sold 9,309 shares of the business’s stock in a transaction on Friday, May 6th. The shares were sold at an average price of $12.58, for a total value of $117,107.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder John B. Ph D. Md Simpson sold 75,111 shares of the business’s stock in a transaction on Friday, April 15th. The stock was sold at an average price of $13.11, for a total transaction of $984,705.21. The disclosure for this sale can be found here.

Other hedge funds have recently modified their holdings of the company. Thornburg Investment Management Inc. purchased a new stake in shares of Avinger during the fourth quarter worth $1,199,000. EAM Investors LLC boosted its stake in shares of Avinger by 0.4% in the fourth quarter. EAM Investors LLC now owns 116,261 shares of the medical device company’s stock worth $2,640,000 after buying an additional 457 shares during the last quarter. Paradigm Capital Management Inc. NY boosted its stake in shares of Avinger by 41.8% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 367,056 shares of the medical device company’s stock worth $8,336,000 after buying an additional 108,222 shares during the last quarter. Finally, Morgan Stanley boosted its stake in shares of Avinger by 248.5% in the fourth quarter. Morgan Stanley now owns 146,866 shares of the medical device company’s stock worth $3,335,000 after buying an additional 104,729 shares during the last quarter.

Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses to introduce products based on its lumivascular platform, which is an intravascular image-guided system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.